January 2, 2014 — Imaging research from Western University, London, Canada, has demonstrated that a magnetic resonance imaging (MRI) approach called quantitative susceptibility mapping (QSM) can be an important tool for diagnosing and tracking the progression of multiple sclerosis (MS) and other neurological diseases. QSM allows quantitative measurement of myelin content and iron deposition in the brain. Ravi Menon, Ph.D., Western's Robarts Research Institute, Western University, led the research, which is published in Proceedings of the National Academy of Sciences (PNAS).
 
Menon and his associates, including David Rudko, Ph.D., first author, set out to determine whether QSM was indeed quantitative. Interpretation of QSM data requires the use of a model of the underlying tissue structure. The scientists found that the most common approach to creating QSM images was insufficient to generate quantitative images — images in which myelin content and iron can be measured. They demonstrated this by exploring the orientation dependence of the MRI signal. This particular signal has generally thought to be a constant, but the team showed that it depends on tissue orientation in both cortical grey and white matter, but not in the deep brain structures such as the basal ganglia. All these areas are implicated in MS.
 
They demonstrated the discordance between the models for QSM using a device that rotated a rat's brain, so that it could be scanned from 18 different angles, using a 9.4-T MRI. The brains were then sent to histology for comparison. They found the values depended on the microstructure of the brain such as myelin concentration and integrity, as well as iron deposition. The study also showed, for the first time, the correlation between MRI measurement and histology measurement when the correct model was used.
 
"With this methodology, we now have a quantitative way to interpret myelin and iron concentrations, and in particular, any changes to them over time," said Menon, who holds a Canada Research Chair in Functional Magnetic Resonance Imaging. "We've been doing these scans on MS patients for a while, but nobody knew if it was a valid approach or not. We now know how to interpret the data. It allows us to separate changes in white matter degeneration from other changes such as iron deposition, which in conventional imaging all looks the same."
 
Menon says the next step is to use this new imaging approach to study the changes that occur in MS and find out if it is predictive of disease progression.
 
For more information: cfmm.robarts.ca, www.pnas.org

Related Content

News | Lung Imaging

Sept. 8, 2026 – Brainomix and Endeavor BioMedicines recently presented positive results from the Brainomix AI-driven ...

Time September 09, 2026
arrow
News | Ultrasound Imaging

Sept. 2, 2026 – Sonex Health and The Institute of Advanced Ultrasound Guided Procedures have announced publication of ...

Time September 04, 2026
arrow
News | Radiation Oncology

Sept. 2, 2026 — Children with one of the deadliest forms of brain cancer may benefit from an additional course of ...

Time September 03, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026— A new study from the Harvey L. Neiman Health Policy Institute found that the odds of imaging following an ...

Time September 01, 2026
arrow
News | RSNA

Aug. 18, 2026 —The board of trustees of the Radiological Society of North America's (RSNA) Research & Education (R&E) ...

Time August 24, 2026
arrow
News | Radiology Imaging

Aug. 13, 2026 — Epic's new Care Everywhere Diagnostic Image Exchange allows health systems using Epic to share ...

Time August 21, 2026
arrow
News | Cardiac Imaging

Aug. 20, 2026 – The novel, radiopaque, polymer-based embolic coil from Embolization, Inc. has now surpassed 125 implants ...

Time August 20, 2026
arrow
News | Radiology Business

Aug. 4, 2026 — Canon Medical Systems USA (CMSU) has appointed Tsuneo "Neo" Imai as president and chief executive officer ...

Time August 10, 2026
arrow
News | Radiology Imaging

Aug. 4, 2026 — A new study from the Harvey L. Neiman Health Policy Institute found that the time between an imaging scan ...

Time August 06, 2026
arrow
News | Contrast Agents

Aug. 5, 2026 — Bracco Group is bringing a newly authorized macrocyclic gadolinium-based contrast agent (GBCA) for ...

Time August 05, 2026
arrow
Subscribe Now